Entscheidend wird sein ob es gelingt die Zahl der Einheiten auf wieder auf die 500 Einheiten zu bekommen. Denke die esten Zahlen werden sich auf 360-400 Einheiten belaufen.
Auf Analysten Daten aus 2013 währen wir dann auch einen Kurs von 16-17$.
Date§Research Firm Action From To
Dec 23, 2013 Chardan Capital Markets Upgrade Neutral Buy Dec 10, 2013 Stifel Upgrade Hold Buy
Oct 21, 2013 RBC Capital Mkts Downgrade Outperform Sector Perform Oct 14, 2013 Argus Downgrade Hold Sell Oct 10, 2013 Chardan Capital Markets Downgrade Buy Neutral Oct 10, 2013 Summer Street Research Downgrade Buy Neutral Oct 10, 2013 Barclays Downgrade Overweight Underweight Oct 9, 2013 Maxim Group Downgrade Buy Hold
09-Oct-13 Downgrade Maxim Group Buy → Hold $24 30-Sep-13 Upgrade Oppenheimer Perform → Outperform $23 → $24 30-Sep-13 Reiterated Maxim Group Buy $26 → $24 04-Sep-13 Initiated Chardan Capital Markets Buy $28 26-Feb-13 Reiterated Barclays Overweight $30 → $29 03-Jan-13 Reiterated UBS Buy $29 → $26
Mon, 30 Sep 20:57
Quelle:http://www.i3investor.com/servlets/fdnews/159752.jsp
Investment analysts at JMP Securities decreased their price target on shares of Ariad Pharmaceuticals (NASDAQ:ARIA) to $30.00 in a note issued to investors on Monday, American Banking and Market News reports. The firm currently has a “market outperform” rating on the stock. JMP Securities’ price objective would suggest a potential upside of 63.04% from the company’s current price.
A number of other analysts have also recently weighed in on ARIA. Analysts at Brean Capital cut their price target on shares of Ariad Pharmaceuticals (NASDAQ:ARIA) from $28.00 to $26.00 in a research note to investors on Monday. They now have a “buy” rating on the stock. Separately, analysts at Maxim Group cut their price target on shares of Ariad Pharmaceuticals (NASDAQ:ARIA) from $26.00 to $24.00 in a research note to investors on Monday. They now have a “buy” rating on the stock. Finally, analysts at Oppenheimer upgraded shares of Ariad Pharmaceuticals (NASDAQ:ARIA) from a “market perform” rating to an “outperform” rating in a research note to investors on Monday. They now have a $24.00 price target on the stock, up previously from $23.00. Three analysts have rated the stock with a hold rating and sixteen have given a buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus target price of $26.72. |